002900.SHE Harbin Medisan Pharmaceutical Co Ltd
- Market cap
- CNY 3.12B
- P/E
- -
- P/B
- 1.85x
- ROE
- -7.5%
- Dividend yield
- 3.53%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002900.SHE undervalued?
Graham numberThe Graham number of Harbin Medisan Pharmaceutical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Harbin Medisan Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Harbin Medisan Pharmaceutical Co Ltd yet.
Harbin Medisan Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Harbin Medisan Pharmaceutical Co Ltd
Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium folinate for injection, hydroxylcamptothecine injection, tropisetron hydrochloride f…
Full company profileHarbin Medisan Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Harbin Medisan Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 761M | 1.15B | 2.17B | 2.10B | 1.34B | 946M | 1.03B | 1.19B | 1.13B | 789M | 831M |
| Gross Profit | 467M | 851M | 1.82B | 1.59B | 852M | 633M | 668M | 711M | 579M | 298M | 293M |
| Operating Income | 196M | 253M | 251M | 229M | 35.3M | 455M | 40.6M | 79.0M | 62.0M | -275M | -135M |
| EBITDA | 272M | 327M | 325M | 314M | 123M | 556M | 161M | 204M | 188M | -184M | -106M |
| Net Income | 175M | 181M | 206M | 177M | 29.3M | 351M | 30.2M | 73.7M | 58.7M | -340M | -126M |
| EPS | 0.74 | 0.71 | 0.65 | 0.57 | 0.09 | 1.13 | 0.10 | 0.24 | 0.19 | -1.07 | -0.40 |
| Balance Sheet | |||||||||||
| Total Assets | 1.17B | 2.18B | 2.51B | 2.67B | 2.48B | 3.07B | 3.28B | 3.44B | 3.80B | 3.46B | 3.18B |
| Total Liabilities | 358M | 349M | 544M | 820M | 691M | 949M | 1.22B | 1.29B | 1.64B | 1.68B | 1.50B |
| Shareholders' Equity | 808M | 1.83B | 1.95B | 1.83B | 1.78B | 2.10B | 2.04B | 2.14B | 2.16B | 1.77B | 1.68B |
| Cash & Short-term Investments | 129M | 355M | 557M | 1.17B | 1.02B | 1.11B | 1.29B | 1.05B | 842M | 461M | 338M |
| Total Debt | 106M | 7.35M | 58.0M | 180M | 270M | 488M | 657M | 513M | 715M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 231M | 223M | 292M | 320M | -4.51M | -12.5M | 145M | 35.7M | 30.7M | -36.3M | - |
| Capital Expenditure | 93.9M | 105M | 78.4M | 199M | 146M | 73.9M | 89.2M | 300M | 346M | 248M | 76.0M |
| Free Cash Flow | 137M | 119M | 214M | 122M | -150M | -86.5M | 55.4M | -264M | -316M | -284M | 35.1M |
| Ratios | |||||||||||
| ROE | 21.7% | 9.9% | 10.6% | 9.7% | 1.7% | 16.7% | 1.5% | 3.4% | 2.7% | -19.2% | -7.5% |
| ROA | 15.0% | 8.3% | 8.2% | 6.6% | 1.2% | 11.4% | 0.9% | 2.1% | 1.5% | -9.8% | -4.0% |
| Net Profit Margin | 23.0% | 15.8% | 9.5% | 8.4% | 2.2% | 37.1% | 2.9% | 6.2% | 5.2% | -43.0% | -15.1% |
| Debt to Equity | 0.13x | 0.00x | 0.03x | 0.10x | 0.15x | 0.23x | 0.32x | 0.24x | 0.33x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Harbin Medisan Pharmaceutical Co Ltd dividends
- Dividend yield
- 3.53%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 110M | 0.35 | - |
| 2024 | CNY 105M | 0.34 | 178.2% |
| 2023 | CNY 41.0M | 0.13 | 55.7% |
| 2022 | CNY 99.1M | 0.33 | 328.2% |
| 2021 | CNY 24.8M | 0.08 | 7.1% |
| 2020 | CNY 86.7M | 0.27 | 295.8% |
| 2019 | CNY 203M | 0.65 | 114.3% |
| 2018 | CNY 107M | 0.34 | 52.2% |
| 2017 | CNY 92.4M | 0.36 | 51.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on Jun 13, 2018.
Who owns Harbin Medisan Pharmaceutical Co Ltd
- Insiders 66.00%
- Institutions 1.55%
- Public & others 32.45%
- Shares outstanding 316M
- Free float 106M
Harbin Medisan Pharmaceutical Co Ltd company profile
- Company name
- Harbin Medisan Pharmaceutical Co Ltd
- Ticker
- 002900.SHE
- ISIN
- CNE1000032V9
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,086
- Fiscal year end
- December
- Address
- The middle part of Beijing Road, Harbin, China, 150025
- Phone
- 86 451 8560 8888
- Website
- medisan.com.cn
About Harbin Medisan Pharmaceutical Co Ltd
Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium folinate for injection, hydroxylcamptothecine injection, tropisetron hydrochloride for injection, tropisetron hydrochloride and glucose injection, gabexate mesylate for injection, bismuth potassium citrate granules, pantoprazole sodium for injection, ambroxol hydrochloride and glucose injection, asarone for injection, paracetamol and tramadol hydrochloride tablets, rifamycin sodium for injection, lornoxicam for injection, vecuronium bromide for injection, and vitamin c for injection. It also provides manufacture, sale, and retail of pharmaceutical, drug development, technology investment consulting, logistics and transportation, medical devices, food, and cosmetics. Harbin Medisan Pharmaceutical Co., Ltd. was founded in 1996 and is headquartered in Harbin, China.
Harbin Medisan Pharmaceutical Co Ltd management
5- Mr. Jian Fei QinChairman & President · born 1963
- Mr. Zhicheng ZhaoFinancial Director · born 1975
- Mr. Zhen QinExecutive President & Non-Independent Director · born 1991
- Mr. Yan Fei LiangVP, Board Secretary & Director · born 1967
- Dapeng WangAccounting Supervisor